X
Immuno-oncology latecomer GSK shows off PD-1 drug data
https://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/
PD-1
BMS and Nektar to pair Opdivo with natural killer cell drug
BMS and Nektar’s combination latest in frenzied immunotherapy field
Promise for combination approach to cancer
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.